Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from the leader trial by Verma, S. et al.
Key Words: cardiovascular system  
◼ diabetes mellitus, type 2 
◼ glucagon-like peptide-1 ◼ liraglutide 
◼ randomized controlled trial as topic
BACKGROUND: The glucagon-like peptide-1 analog liraglutide reduced 
cardiovascular events and mortality in patients with type 2 diabetes mellitus 
in the LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 
Diabetes). In a post hoc analysis, we evaluated the efficacy of liraglutide in 
those with and without a history of myocardial infarction (MI) and/or stroke.
METHODS: LEADER was a randomized trial of liraglutide (1.8 mg or 
maximum tolerated dose) versus placebo in 9340 patients with type 2 
diabetes mellitus and high cardiovascular risk, with a median follow-up of 
3.8 years. The primary outcome was a composite of cardiovascular death, 
nonfatal MI, or nonfatal stroke (major adverse cardiovascular events). 
Risk groups in this post hoc analysis were defined by history of MI/stroke, 
established atherosclerotic cardiovascular disease without MI/stroke, or 
cardiovascular risk factors alone.
RESULTS: Of the 9340 patients, 3692 (39.5%) had a history of MI/stroke, 
3083 (33.0%) had established atherosclerotic cardiovascular disease 
without MI/stroke, and 2565 (27.5%) had risk factors alone. Major adverse 
cardiovascular events occurred in 18.8% of patients with a history of MI/stroke 
(incidence rate, 5.0 per 100 patient-years), 11.6% of patients with established 
atherosclerotic cardiovascular disease without MI/stroke (incidence rate, 3.0 
per 100 patient-years), and 9.8% of patients with cardiovascular risk factors 
alone (incidence rate, 2.6 per 100 patient-years). Liraglutide reduced major 
adverse cardiovascular events in patients with a history of MI/stroke (322 of 
1865 [17.3%] versus 372 of 1827 patients [20.4%]; hazard ratio, 0.85; 95% 
CI, 0.73–0.99) and in those with established atherosclerotic cardiovascular 
disease without MI/stroke (158 of 1538 [10.3%] versus 199 of 1545 patients 
[12.9%]; hazard ratio, 0.76; 95% CI, 0.62–0.94) compared with placebo. In 
patients with risk factors alone, the hazard ratio for liraglutide versus placebo 
was 1.08 (95% CI, 0.84–1.38, P
interaction=0.11). Similar results were seen for 
secondary outcomes across risk groups.
CONCLUSIONS: In this post hoc analysis of patients with type 2 diabetes 
mellitus and high cardiovascular risk, liraglutide reduced cardiovascular 
outcomes both in patients with a history of MI/stroke and in those with 
established atherosclerotic cardiovascular disease without MI/stroke. The 
cardiovascular effect appeared neutral in patients with cardiovascular risk 
factors alone.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT01179048.
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Despite optimal medical therapy, morbidity and mortality from cardiovascular disease remain significantly higher in patients with diabetes 
mellitus compared with age- and sex-matched indi-
viduals without diabetes mellitus.1–3 In fact, patients 
with diabetes mellitus and a prior ischemic cardiovas-
cular event are at an especially high risk of recurrent 
events.4–6 Although strides have been made with re-
spect to a reduction in macrovascular and microvascular 
events in diabetes mellitus,7 the rise in the prevalence 
of diabetes mellitus poses a substantial cardiovascular 
burden worldwide.
The LEADER trial (Liraglutide and Cardiovascular 
Outcomes in Type 2 Diabetes) demonstrated a 13% 
significant relative risk reduction in major adverse car-
diovascular events (MACE) with liraglutide versus pla-
cebo, both as add-on to standard-of-care treatment, in 
patients with type 2 diabetes mellitus (T2DM) and high 
cardiovascular risk.8
Because the presence of myocardial infarction (MI) 
or stroke is one of the most important risk stratifiers in 
patients with diabetes mellitus and high cardiovascular 
risk,1,9 it is important to evaluate the absolute and rela-
tive benefits of cardiovascular risk reduction approaches 
across the continuum of patients with diabetes mellitus 
with varying cardiovascular risk, ranging from history of 
 
MI/stroke to established atherosclerotic cardiovascular 
disease without a history of MI/stroke and cardiovascu-
lar risk factors alone.
METHODS
The subject-level analysis data sets for the research presented 
in the publication are available from the corresponding author 
on reasonable request.
The design of the LEADER trial (Clinicaltrials.gov 
NCT01179048) has been described previously.8,10 Briefly, 
LEADER was a randomized, double-blind, multicenter, placebo-
controlled, cardiovascular outcomes trial. The trial protocol 
was reviewed and approved by the institutional review board 
or ethics committee at each participating center. All patients 
provided written informed consent before participation. 
Patients
In total, 9340 patients with T2DM with a glycohemoglobin 
level of ≥7.0% and high cardiovascular risk were randomly 
assigned to receive liraglutide 1.8 mg/d (or the maximum tol-
erated dose) or placebo, both as add-on to standard of care, 
and followed up for 3.5 to 5 years. Patients included were 
either >50 years of age with established cardiovascular dis-
ease, defined by the protocol as coronary artery disease, cere-
brovascular disease, peripheral artery disease, New York Heart 
Association class II or III heart failure, or chronic kidney disease 
(estimated glomerular filtration rate <60 mL·min−1·1.73 m−2), 
or >60 years of age with at least 1 additional cardiovascular 
risk factor (microalbuminuria or proteinuria, hypertension and 
left ventricular hypertrophy, left ventricular systolic or diastolic 
dysfunction, or an ankle-brachial index <0.9).
Risk Groups
In this post hoc analysis, we compared the incidence of the 
primary and secondary composite outcomes with liraglutide 
versus placebo in 3 mutually exclusive clinically relevant risk 
groups. Risk groups were defined according to those with 
and without atherosclerotic disease and degree of disease: 
(1) patients with a history of MI/stroke, (2) patients with
established atherosclerotic cardiovascular disease without MI/
stroke (≥50% coronary artery stenosis, percutaneous coro-
nary intervention or coronary artery bypass graft [CABG] sur-
gery, angina pectoris with a positive stress imaging test and/or
asymptomatic ischemia [but no MI], transient ischemic attack,
≥50% intracranial or carotid artery stenosis, and ≥50%
peripheral artery stenosis by imaging or ankle-brachial index
<0.9), or (3) patients with cardiovascular risk factors alone (ie,
those not meeting definitions for the former risk groups such
as those with isolated chronic kidney disease, hypertension
with left ventricular hypertrophy, New York Heart Association
class II or III heart failure, and left ventricular systolic or dia-
stolic dysfunction). This information was investigator-reported
at randomization. The presence of stroke included both isch-
emic and hemorrhagic stroke.
Outcomes
The primary outcome was defined as the first occurrence of 
a MACE (defined as the composite of cardiovascular death, 
Clinical Perspective
What Is New?
• There is a spectrum of cardiovascular events in
people with diabetes mellitus, with about twice the
major adverse cardiovascular events rate in those
with prior myocardial infarction/stroke versus those
with risk factors alone.
• Liraglutide consistently lowered the primary and
expanded major adverse cardiovascular event out-
comes in people with diabetes mellitus and athero-
sclerotic cardiovascular disease regardless of prior
myocardial infarction/stroke history.
• In people with diabetes mellitus with risk factors
alone, liraglutide appeared safe but not superior to
placebo.
What Are the Clinical Implications?
• Liraglutide is an effective antihyperglycemic agent
for the reduction of cardiovascular events in people
with diabetes mellitus who had a prior myocardial
infarction or stroke or in those who have athero-
sclerotic cardiovascular disease but have not yet
had a myocardial infarction or stroke.
• In people with type 2 diabetes mellitus who only
have risk factors, liraglutide is safe but, in the short
term, is not associated with reductions in major
adverse cardiovascular events.
nonfatal MI, or nonfatal stroke). A prespecified, key secondary 
expanded composite outcome included coronary revascular-
ization, hospitalization for unstable angina, or heart failure in 
addition to MACE. Furthermore, prespecified secondary end 
points were time to first event of the individual components 
of the expanded composite outcomes and all-cause death. 
We also examined renal and metabolic outcomes in these 3 
risk groups (see ‘Detailed description of renal and metabolic 
outcomes and statistical considerations’, page 1 in the online-
only Data Supplement).
The cardiovascular and renal outcomes were adjudicated 
by an independent event adjudication committee of experts 
blinded to the randomization.8 Furthermore, the event adjudi-
cation committee assessed whether MI/stroke was fatal or non-
fatal, through which fatal events were linked to subsequent 
cardiovascular death. Serious and nonserious medical adverse 
events of special interest were reported by the investigator.
Statistical Analysis
The time from randomization to the first occurrence of the 
outcome was analyzed with a Cox proportional hazards 
model on all randomized subjects. The hazard ratios (HRs) and 
P values between risk groups were estimated with multivari-
able adjustment for prespecified baseline factors (sex, region, 
baseline age, diabetes duration, baseline antidiabetic medi-
cation, smoking history [never/prior/current], and estimated 
glomerular filtration rate at screening)8 and for treatment 
allocation (liraglutide versus placebo). The treatment effect of 
liraglutide versus placebo within risk groups was estimated 
with a Cox proportional hazards regression model, with 
treatment, risk group, and the interaction of both as factors, 
and adjusted for the above prespecified baseline factors.8 
Furthermore, Kaplan-Meier curves were used to examine the 
association between treatment groups within risk groups and 
the outcome of interest. An interaction value of P<0.05 indi-
cated a significant difference in the treatment HRs across the 
3 risk groups. No adjustment for multiple testing was per-
formed. All patients who underwent randomization were 
included in the analyses and followed up from the time of 
randomization until death or the end of follow-up. To evalu-
ate any potential treatment interaction with prior cardiovas-
cular disease, sensitivity analyses were conducted that were 
stratified by investigator-reported history of MI/stroke alone or 
including percutaneous coronary intervention or CABG or by 
carotid stenosis in addition to history of MI/stroke. Sensitivity 
analyses in relation to treatment differences were performed, 
with adjustment for all-cause death as a competing risk using 
the Fine and Gray regression method.8,11 The number needed 
to treat was calculated from the predicted survival rates at 3 
years after randomization.12
Serious and nonserious medical adverse events of special 
interest between the 3 treatment groups were summarized.
RESULTS
Baseline Characteristics
Of the 9340 patients, 3692 (39.5%) had a history of 
MI/stroke, 3083 (33.0%) had evidence of 
atherosclerotic cardiovascular disease without an MI/
stroke, and 
2565 (27.5%) had cardiovascular risk factors alone. The 
baseline demographics and cardiovascular histories of 
these 3 groups are detailed in Tables 1 and 2, respec-
tively. Patients with a history of MI/stroke had a higher 
frequency of cardiovascular risk factors. Of patients with 
a history of MI/stroke, 76.0% had a history of MI, and 
28.1% had a previous ischemic stroke; revascularization 
with percutaneous coronary intervention had been per-
formed in 43.3%, and 24.5% had a history of CABG 
compared with 31.4% and 20.3%, respectively, in pa-
tients with atherosclerotic cardiovascular disease with-
out an MI/stroke. More patients with a history of MI/
stroke had evidence of left ventricular systolic dysfunc-
tion and heart failure. Median follow-up was 3.8 years.
Risk of Cardiovascular Events and 
Mortality According to Risk Groups 
Regardless of Treatment
Patients with a history of MI/stroke had the highest risk 
of MACE (694 events of 3692 [18.8%]), followed by pa-
tients with established atherosclerotic cardiovascular dis-
ease without a history of MI/stroke (357 of 3083 [11.6%]) 
and patients with cardiovascular risk factors alone (251 
of 2565 [9.8%]). The adjusted HRs for MACE were 2.13 
(95% CI, 1.84–2.47; P<0.0001) and 1.29 (95% CI, 1.10–
1.52; P=0.0021) in patients with a history of MI/stroke 
and those with established atherosclerotic cardiovascular 
disease without MI/stroke, respectively, compared with 
patients with cardiovascular risk factors alone. Incidence 
rates of MACE were 5.0 per 100 person-years of observa-
tion (PYO) in patients with a history of MI/stroke, 3.0 per 
100 PYO in patients with established atherosclerotic car-
diovascular disease without MI/stroke, and 2.6 per 100 
PYO in those with cardiovascular risk factors alone.
Similar results were obtained for expanded MACE 
when patients with MI/stroke (1052 of 3692 [28.5%]; 
HR, 2.27; 95% CI, 2.01–2.57; P<0.0001) and with es-
tablished atherosclerotic cardiovascular disease without 
MI/stroke (597 of 3083 [19.4%]; HR, 1.52; 95% CI, 
1.34–1.74; P<0.0001) were compared with those with 
cardiovascular risk factors alone (361 of 2565 [14.1%]). 
Incidence rates of expanded MACE were 7.5 per 100 
PYO in patients with a history of MI/stroke, 5.1 per 100 
PYO in patients with established atherosclerotic cardio-
vascular disease without MI/stroke, and 3.7 per 100 
PYO in those with cardiovascular risk factors alone.
Incidence rates for time to the first of the individual 
components of the primary and secondary outcomes 
in the 3 groups (history of MI/stroke versus established 
atherosclerotic cardiovascular disease without MI/stroke 
versus cardiovascular risk factors alone) were as follows: 
cardiovascular death (1.9 versus 1.1 versus 1.1 per 100 
PYO), nonfatal MI (2.3 versus 1.5 versus 1.0 per 100 
PYO), nonfatal stroke (1.3 versus 0.8 versus 0.7 per 100 
PYO), coronary revascularization (3.3 versus 2.4 versus 
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Male, n (%) 2693 (72.9) 1922 (62.3) 1388 (54.1) 1333 (73.0) 1360 (72.9) 952 (61.6) 970 (63.1) 707 (54.4) 681 (53.8)
Age (SD), y 63.4 (7.5) 64.3 (7.4) 65.5 (6.4) 63.6 (7.5) 63.3 (7.5) 64.4 (7.5) 64.2 (7.3) 65.5 (6.3) 65.5 (6.6)
BMI (SD), kg/m2 32.0 (5.9) 32.4 (6.1) 33.4 (6.9) 31.9 (6.0) 32.0 (5.9) 32.4 (6.2) 32.4 (6.1) 33.3 (6.7) 33.4 (7.0)
Diabetes mellitus 
duration (SD), y
12.6 (8.1) 13.0 (8.0) 12.9 (7.9) 12.7 (8.2) 12.4 (8.0) 13.2 (8.1) 12.9 (7.8) 13.2 (8.0) 12.7 (7.7)
HbA1c (SD), % 8.7 (1.5) 8.6 (1.5) 8.8 (1.6) 8.7 (1.5) 8.8 (1.6) 8.6 (1.5) 8.6 (1.5) 8.7 (1.5) 8.8 (1.6)
HbA1c (SD), mmol/mol 71.9 (16.8) 70.4 (16.1) 72.2 (17.2) 71.5 (16.4) 72.4 (17.1) 70.3 (15.9) 70.6 (16.3) 71.7 (16.6) 72.8 (17.7)
Smoking status, n (%)
 Current smoker 516 (14.0) 343 (11.1) 271 (10.6) 254 (13.9) 262 (14.0) 167 (10.8) 176 (11.4) 142 (10.9) 129 (10.2)
 Never smoker 1251 (33.9) 1345 (43.6) 1274 (49.7) 624 (34.2) 627 (33.6) 660 (42.7) 685 (44.5) 636 (48.9) 638 (50.4)
 Previous smoker 1925 (52.1) 1395 (45.2) 1020 (39.8) 949 (51.9) 976 (52.3) 718 (46.5) 677 (44.0) 522 (40.2) 498 (39.4)
SBP (SD), mm Hg 134.7 (17.7) 135.9 (17.6) 137.5 (17.8) 134.8 (17.8) 134.7 (17.7) 136.2 (17.6) 135.7 (17.6) 137.1 (17.7) 137.9 (17.9)
DBP (SD), mm Hg 77.0 (10.2) 76.7 (10.2) 77.7 (10.3) 76.8 (10.2) 77.2 (10.2 76.6 (10.0) 76.9 (10.4) 77.7 (10.2) 77.6 (10.5)
Heart rate (SD), bpm 71.9 (11.4) 72.3 (11.2) 74.0 (11.4) 71.6 (11.7) 72.1 (11.2) 72.4 (11.3) 72.2 (11.1) 74.0 (11.1) 74.1 (11.7)
eGFR from the 
MDRD equation (SD), 
mL·min−1·1.73 m−2 
81.5 (27.6) 82.3 (26.4) 76.4 (27.8) 81.5 (27.8) 81.6 (27.4) 82.6 (26.0) 81.9 (26.8) 76.9 (27.3) 76.0 (28.2)
Renal function
 Severe (<30 
mL·min−1·1.73 m−2), 
n (%)
76 (2.1) 41 (1.3) 107 (4.2) 34 (1.9) 42 (2.3) 17 (1.1) 24 (1.6) 56 (4.3) 51 (4.0)
 Moderate (30–59 
mL·min−1·1.73 m−2), 
n (%)
727 (19.7) 567 (18.4) 640 (25.0) 353 (19.3) 374 (20.1) 279 (18.1) 288 (18.7) 303 (23.3) 337 (26.6)
 Mild (60–89 
mL·min−1·1.73 m−2), 
n (%)
1549 (42.0) 1322 (42.9) 1036 (40.4) 777 (42.5) 772 (41.4) 651 (42.1) 671 (43.6) 547 (42.1) 489 (38.7)
 Normal (≥90 
mL·min−1·1.73 m−2), 
n (%)
1340 (36.3) 1153 (37.4) 782 (30.5) 663 (36.3) 677 (36.3) 598 (38.7) 555 (36.1) 394 (30.3) 388 (30.7)
Total cholesterol (SD), 
mg/dL
165.1 (43.6) 169.9 (46.5) 177.8 (45.0) 166.0 (44.5) 164.3 (42.6) 169.3 (47.1) 170.4 (45.9) 176.7 (43.7) 178.9 (46.4)
LDL cholesterol (SD), 
mg/dL
86.9 (35.7) 89.6 (36.7) 95.0 (36.1) 87.6 (35.9) 86.2 (35.4) 89.0 (35.9) 90.1 (37.5) 94.7 (36.0) 95.4 (36.2)
HDL cholesterol (SD), 
mg/dL
43.6 (11.6) 45.6 (12.3) 47.7 (12.9) 43.8 (11.4) 43.5 (11.7) 45.6 (12.5) 45.6 (12.1) 47.6 (12.7) 47.8 (13.0)
Triglycerides (SD), mg/dL 183.2 (133.3) 183.2 (150.3) 183.9 (140.5) 183.7 (143.0) 182.8 (123.0) 183.3 (171.2) 183.1 (126.0) 180.3 (141.2) 187.5 (139.8)
Antihypertensive 
therapy, n (%)
3473 (94.1) 2854 (92.6) 2304 (89.8) 1712 (93.7) 1761 (94.4) 1421 (92.0) 1433 (93.2) 1169 (89.9) 1135 (89.7)
Diuretics, n (%) 1533 (41.5) 1207 (39.2) 1166 (45.5) 767 (42.0) 766 (41.1) 619 (40.1) 588 (38.2) 567 (43.6) 599 (47.4)
Lipid-lowering drugs, 
n (%)
3073 (83.2) 2364 (76.7) 1642 (64.0) 1500 (82.1) 1573 (84.3) 1173 (75.9) 1191 (77.4) 842 (64.8) 800 (63.2)
Platelet aggregation 
inhibitors, n (%)
2937 (79.6) 2252 (73.0) 1137 (44.3) 1450 (79.4) 1487 (79.7) 1108 (71.7) 1144 (74.4) 563 (43.3) 574 (45.4)
Antithrombotic 
medications, n (%)
300 (8.1) 160 (5.2) 163 (6.4) 151 (8.3) 149 (8.0) 80 (5.2) 80 (5.2) 83 (6.4) 80 (6.3)
Blood glucose-lowering 
drugs, excluding insulin, 
n (%)
3234 (87.6) 2755 (89.4) 2253 (87.8) 1605 (87.8) 1629 (87.3) 1385 (89.6) 1370 (89.1) 1139 (87.6) 1114 (88.1)
Insulin treatment, n (%) 1697 (46.0) 1338 (43.4) 1134 (44.2) 851 (46.6) 846 (45.4) 697 (45.1) 641 (41.7) 583 (44.8) 551 (43.6)
Insulin-naive, n (%) 1995 (54.0) 1745 (56.6) 1431 (55.8) 976 (53.4) 1019 (54.6) 848 (54.9) 897 (58.3) 717 (55.2) 714 (56.4)
BMI indicates body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycohemoglobin; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; MDRD, Modified Diet in Renal Disease; MI, myocardial infarction; SBP, systolic blood pressure; and SD, standard deviation.
1.0 per 100 PYO), hospitalization for unstable angina (1.0 
versus 0.7 versus 0.2 per 100 PYO), and hospitalization 
for heart failure (1.7 versus 1.1 versus 1.0 per 100 PYO). 
All-cause death was also higher in patients with history 
of MI/stroke compared with patients with established 
atherosclerotic cardiovascular disease without MI/stroke 
or those with cardiovascular risk factors alone (incidence 
rates, 2.9 versus 1.9 versus 2.0 per 100 PYO, respectively).
Effects of Liraglutide on Cardiovascular 
Events and Mortality in Patients With a 
History of MI and/or Stroke
The primary composite end point occurred in 322 of 
1865 patients (17.3%) with an incidence rate of 4.6 per 
100 PYO in the liraglutide group compared with 372 of 
the 1827 patients (20.4%) with an incidence rate of 5.4 













With Prior MI/Stroke 
(n=3692), n (%)
CVD Without MI or Stroke 
(n=3083), n (%)
Cardiovascular Risk Factors 















2807 (76.0) 0 (0) 0 (0) 1373 (75.2) 1434 (76.9) 0 (0) 0 (0) 0 (0) 0 (0)
Arrhythmia 643 (17.4) 494 (16.0) 302 (11.8) 314 (17.2) 329 (17.6) 244 (15.8) 250 (16.3) 163 (12.5) 139 (11.0)
Heart failure 766 (20.7) 506 (16.4) 395 (15.4) 387 (21.2) 379 (20.3) 243 (15.7) 263 (17.1) 202 (15.5) 193 (15.3)
 NYHA class I 202 (5.5) 104 (3.4) 42 (1.6) 100 (5.5) 102 (5.5) 47 (3.0) 57 (3.7) 22 (1.7) 20 (1.6)
 NYHA class II 447 (12.1) 341 (11.1) 303 (11.8) 223 (12.2) 224 (12.0) 168 (10.9) 173 (11.2) 155 (11.9) 148 (11.7)
 NYHA class III 106 (2.9) 58 (1.9) 50 (1.9) 56 (3.1) 50 (2.7) 25 (1.6) 33 (2.1) 25 (1.9) 25 (2.0)
 Ischemic heart 
disease
2795 (75.7) 2264 (73.4) 0 (0) 1386 (75.9) 1409 (75.5) 1131 (73.2) 1133 (73.7) 0 (0) 0 (0)




289 (7.8) 555 (18.0) 0 (0) 147 (8.0) 142 (7.6) 271 (17.5) 284 (18.5) 0 (0) 0 (0)
 Unstable angina 283 (7.7) 497 (16.1) 0 (0) 139 (7.6) 144 (7.7) 240 (15.5) 257 (16.7) 0 (0) 0 (0)
 Non–ST-segment–
elevation MI
599 (16.2) 0 (0) 0 (0) 302 (16.5) 297 (15.9) 0 (0) 0 (0) 0 (0) 0 (0)
 ST-segment–
elevation MI
869 (23.5) 0 (0) 0 (0) 437 (23.9) 432 (23.2) 0 (0) 0 (0) 0 (0) 0 (0)
PCI performed 1599 (43.3) 969 (31.4) 0 (0) 790 (43.2) 809 (43.4) 476 (30.8) 493 (32.1) 0 (0) 0 (0)
CABG performed 906 (24.5) 625 (20.3) 0 (0) 438 (24.0) 468 (25.1) 311 (20.1) 314 (20.4) 0 (0) 0 (0)
Left ventricular 
systolic dysfunction
619 (16.8) 250 (8.1) 130 (5.1) 308 (16.9) 311 (16.7) 112 (7.2) 138 (9.0) 58 (4.5) 72 (5.7)
Left ventricular 
diastolic dysfunction
580 (15.7) 487 (15.8) 514 (20.0) 317 (17.4) 263 (14.1) 225 (14.6) 262 (17.0) 257 (19.8) 257 (20.3)
Hypertension 3356 (90.9) 2815 (91.3) 2340 (91.2) 1662 (91.0) 1694 (90.8) 1403 (90.8) 1412 (91.8) 1185 (91.2) 1155 (91.3)
Ischemic stroke 1038 (28.1) 0 (0) 0 (0) 526 (28.8) 512 (27.5) 0 (0) 0 (0) 0 (0) 0 (0)
Transient ischemic 
attack
265 (7.2) 302 (9.8) 0 (0) 146 (8.0) 119 (6.4) 164 (10.6) 138 (9.0) 0 (0) 0 (0)
Hemorrhagic stroke 103 (2.8) 0 (0) 0 (0) 50 (2.7) 53 (2.8) 0 (0) 0 (0) 0 (0) 0 (0)
Intracranial artery 
stenosis
80 (2.2) 30 (1.0) 0 (0) 37 (2.0) 43 (2.3) 9 (0.6) 21 (1.4) 0 (0) 0 (0)
Carotid artery 
stenosis
342 (9.3) 357 (11.6) 0 (0) 162 (8.9) 180 (9.7) 170 (11.0) 187 (12.2) 0 (0) 0 (0)
Peripheral artery 
disease in lower 
extremities
404 (10.9) 763 (24.7) 0 (0) 205 (11.2) 199 (10.7) 395 (25.6) 368 (23.9) 0 (0) 0 (0)
>50% stenosis of 
the coronary, carotid,
or other arteries
1294 (35.0) 1084 (35.2) 0 (0) 650 (35.6) 644 (34.5) 541 (35.0) 543 (35.3) 0 (0) 0 (0)
CABG indicates coronary artery bypass graft; CVD, cardiovascular disease; MI, myocardial infarction; NYHA, New York Heart Association; and PCI, percutaneous 
coronary intervention.
 
per 100 PYO in the placebo group (HR, 0.85; 95% CI, 
0.73–0.99). Time to the first o f t he i ndividual compo-
nents of the 3-point MACE was consistently numerically 
reduced with liraglutide, including cardiovascular death 
(HR, 0.80; 95% CI, 0.63–1.02), nonfatal MI (HR, 0.83; 
95% CI, 0.67–1.03), and nonfatal stroke (HR, 0.95; 95% 
CI, 0.71–1.27; Figures 1 and 2). All-cause death was nu-
merically reduced by 10% (HR, 0.90; 95% CI, 0.74–1.09; 
Figure 2). Liraglutide treatment significantly reduced the 
key secondary expanded end point (7.1 events per 100 
PYO) compared with the placebo group (8.0 events per 
PYO; HR, 0.88; 95% CI, 0.78–0.99; Figure 2).
Effects of Liraglutide on Cardiovascular 
Events in Patients With a History of 
Established Atherosclerotic Cardiovascular 
Disease Without MI/Stroke
The primary composite end point occurred in 158 
of the 1538 patients (10.3%) with an incidence rate 
of 2.7 PYO in the liraglutide group compared with 
199 of the 1545 patients (12.9%) with an incidence 
rate of 3.4 per 100 PYO in the placebo group (HR, 
0.76; 95% CI, 0.62–0.94). Individual components 
of 3-point MACE were consistently reduced with li-
raglutide, including cardiovascular death (HR, 0.59; 
95% CI, 0.41–0.84), nonfatal MI (HR, 0.91; 95% CI, 
0.68–1.22), and nonfatal stroke (HR, 0.68; 95% CI, 
0.45–1.03; (Figures  1 and 2). All-cause death was 
reduced by 34% (HR, 0.66; 95% CI, 0.51–0.86; Fig-
ure  2 and Figure I in the online-only Data Supple-
ment). Liraglutide treatment also showed consistent 
reduction of the key expanded secondary end point 
(incidence rate, 4.4 per 100 PYO) compared with 
placebo (incidence rate, 5.7 per 100 PYO; HR, 0.74; 
95% CI, 0.63–0.87; Figure 2).
Effects of Liraglutide on Cardiovascular 
Events in Patients With Cardiovascular 
Risk Factors Alone
In patients with cardiovascular risk factors alone, the 
primary composite end point occurred in 128 of 1265 
patients (10.1%) with an incidence rate of 2.6 per 100 
PYO in the liraglutide group compared with 123 of the 
1300 patients (9.5%) with an incidence rate of 2.5 per 
100 PYO in the placebo group (HR, 1.08; 95% CI, 0.84–
1.38). The HRs for liraglutide versus placebo for time to 
the first of the individual components of the 3-point 
MACE were as follows: 0.99 (95% CI, 0.67–1.46) for 
cardiovascular death, 1.00 (95% CI, 0.67–1.49) for 
nonfatal MI, and 1.12 (95% CI, 0.68–1.82) for nonfa-
tal stroke (Figures 1 and 2). The HR for all-cause death 
was 0.95 (95% CI, 0.72–1.27; Figure  2). Liraglutide 
treatment showed a similar trend for the key secondary 




Figure 1. Occurrence of the primary composite outcome (A), cardiovascular (CV) death (B), nonfatal myocardial infarction (MI; C), and nonfatal 
stroke (D), stratified by history of MI and/or stroke, established cardiovascular disease (CVD) without MI/stroke, or cardiovascular risk factors alone. 
Primary composite end point (cardiovascular death, nonfatal MI, or nonfatal stroke) from randomization to follow-up. The x axis was truncated at 54 months 
because <10% of patients remained in the trial after this time point. HR indicates hazard ratio between treatment groups (liraglutide vs placebo).
compared with the placebo group (incidence rate, 3.5 
per 100 PYO; HR, 1.12; 95% CI, 0.91–1.38; Figure 2).
Comparing the Cardiovascular Effects of 
Liraglutide Across Risk Groups
No statistically significant i nteractions w ere f ound 
across risk groups for the primary end point 
(Pinteraction=0.11), cardiovascular death (Pinteraction=0.19), 
nonfatal MI (Pinteraction=0.71), or nonfatal stroke 
(Pinteraction=0.28), indicating no statistical differences 
across the subgroups in these post hoc analyses (Fig-
ures  1 and 2). The interaction for the expanded key 
secondary end point was significant (Pinteraction=0.01). Li-
raglutide appeared to reduce cardiovascular outcomes 
consistently in patients with history of MI/stroke and 
in those with evidence of established atherosclerotic 
cardiovascular disease without MI/stroke. However, in 
patients with cardiovascular risk factors alone, liraglu-
tide seemed more neutral with respect to the primary 
and expanded composite end point.
Analyses of Number Needed to Treat
The number needed to treat to prevent a first MACE 
with liraglutide compared with placebo over 3 years 
was 39 in patients with a history of MI/stroke and 44 in 
patients with established atherosclerotic cardiovascular 
disease without MI/stroke. The number needed to treat 
for liraglutide to prevent 1 cardiovascular death was 82 
and 63 in these respective risk groups.
Sensitivity Analysis
In separate subanalyses based on the total LEADER 
population, we stratified by history of MI/stroke 
alone. Liraglutide reduced cardiovascular outcomes 
regardless of baseline history of MI and/or stroke 
for the primary end point (Pinteraction=0.56) and for 
the key secondary expanded composite end point 
(Pinteraction=0.90). Furthermore, the treatment effect of 
liraglutide on nonfatal MI (Pinteraction=0.39) or nonfa-
tal stroke (Pinteraction=0.64) was also similar in patients 
with and without a history of MI/stroke. Liraglutide 
reduced rates of cardiovascular mortality similarly 
in patients with and without a history of MI/stroke 
(Pinteraction=0.79; Figure I in the online-only Data Sup-
plement). After stratification by known cerebrovascu-
lar or coronary artery disease, defined as those with a 
history of CABG, percutaneous coronary intervention, 
or carotid revascularization in addition to MI/stroke, 
results were similar with comparable relative risk re-
Figure 2. Occurrence of cardiovascular outcomes stratified by history of myocardial infarction (MI)/stroke, established cardiovascular (CV) disease 
(CVD) without MI/stroke, or cardiovascular risk factors alone. 
N refers to the number of patients with an event (as a proportion of the full analysis set). Lira indicates liraglutide; MACE, major adverse cardiovascular event; and 
PYO, person-years of observation. *Including fatal and nonfatal events.
ductions for the primary and expanded key second-
ary end points with liraglutide. Greater absolute risk 
reductions were noted in patients with a history of 
MI/stroke and/or coronary/cerebral revascularization 
procedures. Furthermore, for individual components 
of the expanded composite end point, consistency in 
risk reductions was observed (Figure II in the online-
only Data Supplement).
Finally, sensitivity analyses taking into account all-
cause death as a competing risk factor showed similar 
results for the treatment differences (Figure III in the 
online-only Data Supplement).
Efficacy of Liraglutide on Nephropathy 
Outcomes, Glycohemoglobin, Weight, 
and Systolic Blood Pressure According to 
Risk Groups
The composite renal outcome was consistently reduced 
in patients with MI/stroke (HR, 0.71; 95% CI, 0.54–0.94) 
and in those with established atherosclerotic cardiovas-
cular disease without a history of MI/stroke (HR, 0.66; 
95% CI, 0.49–0.90) and numerically lower in those 
with cardiovascular risk factors alone (HR, 0.92; 95% 
CI, 0.71–1.19; Pinteraction=0.23).
Similar effects of liraglutide across risk groups were 
observed within efficacy parameters: d ifferences in g ly-
cohemoglobin reduction resulting from treatment with 
liraglutide versus placebo from baseline to the 3-year visit 
were −0.40% (95% CI, −0.50 to −0.31) in patients with 
a history of MI/stroke, −0.43% (95% CI, −0.53 to −0.33) 
in those with established atherosclerotic cardiovascular 
disease without a history of MI/stroke, and −0.34% (95% 
CI, −0.45 to −0.23) in those with cardiovascular risk fac-
tors alone (Pinteraction=0.48). Differences in weight reduc-
tion resulting from treatment were also consistent in all 
risk groups: −2.23 kg (95% CI, −2.67 to −1.79), −2.16 kg 
(95% CI, −2.64 to −1.69), and −2.43 kg (95% CI, −2.95 
to −1.91), respectively (Pinteraction=0.74). Furthermore, no 
differences in treatment effects of liraglutide on systolic 
blood pressure were seen across groups (Pinteraction=0.83).
Adverse Events
Adverse events are listed in Table I in the online-only Data 
Supplement. Overall, adverse event percentages were 
64.9% in patients with a history of MI/stroke, 61.1% 
in those with established atherosclerotic cardiovascular 
disease without MI/stroke, and 57.3% in those with 
cardiovascular risk factors alone. The proportion of pa-
tients with any adverse events was similar between the 
liraglutide and placebo groups in patients with a history 
of MI/stroke (65.0% versus 64.8%), in patients with es-
tablished atherosclerotic cardiovascular disease without 
MI/stroke (62.2% versus 60.0%), and in patients with 
cardiovascular risk factors alone (58.6% versus 56.1%). 
 
Similar results were obtained for severe adverse events 
and serious adverse events. However, compared with 
patients on placebo, more patients on liraglutide per-
manently discontinued treatment because of adverse 
events: for patients with a history of MI/stroke, 10.8% 
versus 8.3%; for those with established atherosclerotic 
cardiovascular disease without MI/stroke, 8.3% versus 
6.3; and for those with cardiovascular risk factors alone, 
9.3% versus 7.0%, respectively. The most frequently re-
ported adverse events were gastrointestinal symptoms, 
which are well-known side effects of glucagon-like pep-
tide-1 receptor agonists.
DISCUSSION
In this post hoc analysis of the LEADER trial including 
patients with T2DM and high cardiovascular risk, we 
have shown that patients with a history of MI/stroke 
had a nearly 2-fold greater risk of MACE relative to 
those without. In addition, we have demonstrated a 
consistent level of benefit on all cardiovascular end 
points, including cardiovascular death, associated with 
the use of liraglutide compared with placebo in pa-
tients with a history of MI/stroke at baseline and in 
those with established cardiovascular disease with-
out MI/stroke. Similar observations were made when 
patients were further stratified by baseline history 
of coronary or cerebral revascularization. In patients 
with cardiovascular risk factors alone, the estimated 
HRs—although no significant interaction between risk 
groups was found for the primary outcome and no cor-
rection for multiplicity was performed—may suggest 
that liraglutide had a neutral effect on cardiovascular 
outcomes. This is consistent with previous analyses of 
the LEADER trial; however, subgroups in analyses are 
overlapping.8,13 Taken together, these data indicate 
that the cardiovascular benefits of liraglutide are ob-
served across a clinically relevant continuum of risk in 
T2DM with atherosclerosis or prior ischemic events. 
The lack of apparent cardiovascular benefit in patients 
with T2DM and cardiovascular risk factors alone may 
suggest either a threshold effect or that a longer du-
ration of therapy is required to demonstrate cardio-
vascular efficacy. However, it could also be a random 
finding resulting from multiplicity issues in post hoc 
analyses. The finding is in line with other trials that 
also showed a greater effect of intervention on cardio-
vascular outcomes for patients at higher cardiovascular 
risk.14–19 The renal composite outcome, glycohemoglo-
bin, weight, and systolic blood pressure were reduced 
with liraglutide treatment independently of risk group.
Patients recruited into the LEADER trial were catego-
rized as being either >50 years of age with established 
cardiovascular or chronic kidney disease or >60 years of 
age with 1 additional cardiovascular risk factor (micro-
albuminuria or proteinuria, hypertension and left ven-
tricular hypertrophy, left ventricular systolic or diastolic 
dysfunction, or an ankle-brachial index <0.9). Hence, 
although this type of enrollment strategy was effective 
in identifying patients with T2DM at high risk of de-
veloping cardiovascular events during the trial, it was 
not ideally suited to provide practical information to 
help physicians decide whether the benefits of liraglu-
tide may be seen in patients with or without a history 
of atherosclerotic cardiovascular disease treated within 
a duration of time similar to that of the LEADER trial. 
Clinicians often base decisions on risk reduction thera-
pies on the presence or absence of prior MI/stroke or 
other established atherosclerotic cardiovascular disease 
(secondary prevention) or on evidence of risk factors 
alone (primary prevention)1,9; hence, the assessment of 
cardiovascular effects based on these categories is im-
portant. When we examine the outcomes on the basis 
of the presence of MI/stroke, there is no heterogeneity 
with respect to the relative benefits of liraglutide on 
cardiovascular outcomes; however, a more neutral re-
sult is observed in those with cardiovascular risk factors 
alone. There is, of course, a large overlap between the 
>60 years of age enrollment stratum and the subgroup
of patients with cardiovascular risk factors alone, and
the present finding of neutrality is in concordance with
the previous subgroup analysis of LEADER, in which an
actual interaction between the 2 recruitment strata was
detected, suggesting a differential treatment effect of
liraglutide in these subgroups.8
Recently, the EXSCEL trial (Exenatide Study of Cardio-
vascular Event Lowering) reported cardiovascular out-
comes with exenatide, an exendin-4–based glucagon-
like peptide-1 receptor agonist.17 Similar to LEADER, this 
trial recruited a patient population with T2DM, estab-
lished cardiovascular disease, and multiple risk factors. 
Although the primary outcome and mortality showed 
directional consistency with LEADER, the primary out-
come was not significant with respect to superiority. In 
keeping with subgroup analyses in LEADER, the HR for 
the primary outcome was 0.90 (95% CI, 0.82–1.00) in 
EXSCEL patients with a prior cardiovascular event, de-
fined as clinical manifestation of coronary artery disease, 
ischemic cerebrovascular disease, or atherosclerotic pe-
ripheral artery disease, versus an HR of 0.99 (95% CI, 
0.77–1.28) in those without a history of a cardiovascular 
event. In line with this trend, the subgroup analysis for 
SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other 
Long-Term Outcomes With Semaglutide in Subjects 
With Type 2 Diabetes) showed an HR of 0.72 (95% CI, 
0.55–0.93) for patients with established cardiovascular 
disease and an HR of 1.00 (95% CI, 0.41–2.46) for those 
with cardiovascular risk factors alone (P
interaction=0.49).
20 
For EXSCEL, SUSTAIN-6, and LEADER, the group with-
out established cardiovascular disease, as defined by the 
inclusion criteria, contributed a smaller proportion of 
primary events because of their lower absolute risk.8,18,20
 
In the CANVAS program (Canagliflozin Cardiovascular 
Assessment Study), the cardiovascular outcomes trial in-
vestigating the sodium-glucose cotransporter-2 inhibitor 
canagliflozin,21 patients with T2DM were enrolled who 
were ≥50 years of age and had ≥2 cardiovascular risk 
factors or were ≥30 years of age and with a history of 
cardiovascular event defined as stroke, MI, hospitalization 
for unstable angina, CABG, peripheral revascularization, 
and carotid or peripheral vascular disease or amputation 
resulting from vascular disease. Overall, patients enrolled 
in the CANVAS program were at a lower risk than pa-
tients in LEADER. This is manifested by seemingly lower 
event rates in the 2 cardiovascular risk cohorts in CANVAS 
compared with the LEADER population stratified by MI/
stroke (for MACE: 1.6 versus 2.8 per 100 patient-years 
for the lower-risk groups and 3.7 versus 5.0 per 100 
patient-years for the higher-risk groups, respectively). 
Canagliflozin reduced cardiovascular outcomes primarily 
in patients with prior cardiovascular disease, with a neu-
tral outcome for MACE observed in those in the primary 
prevention subgroup, although consistent benefits were 
seen with respect to heart failure and renal end points.21
There are limitations to these analyses of the LEADER 
data. First, we do not have the time from the self-re-
ported pretrial MI/stroke to randomization. Because the 
first year after the event is usually considered a higher-
risk period for recurrent events,5 efficacy of liraglutide 
in this cohort would have been interesting to evaluate. 
Second, there was a lack of detail in the collection of 
information of history of cardiovascular disease before 
enrollment; for example, baseline assessments of car-
diovascular disease were lacking. In addition, because 
of the lower number of patients within the subgroups 
of interest compared with the overall trial population, 
there is limited statistical power to determine the ef-
fects of liraglutide within these subgroups.
CONCLUSIONS
In this clinically relevant post hoc analysis of the LEADER 
trial, we demonstrate similar relative risk reductions yet 
higher absolute risk reductions of liraglutide on cardio-
vascular events in patients with a history of MI/stroke. 
Liraglutide exerts a consistent benefit in patients with 
established atherosclerotic cardiovascular disease with 
and without a history of MI/stroke; however, it appears 
to be neutral in patients with cardiovascular risk fac-
tors alone. The reason for no apparent cardiovascu-
lar benefit in patients with cardiovascular risk factors 
alone could be that the baseline risk was lower, and 
establishing any potential effect might require a longer 
treatment period or larger sample size. Nevertheless, 
all patients with T2DM regardless of risk group benefit 
from liraglutide treatment in regard to reduced renal 
outcomes, improved glycemic control, weight reduc-
tion, and better blood pressure control. These data 
may 
provide clinicians with important information to help 
identify appropriate patients who would most benefit 
from liraglutide therapy in their practice.
ARTICLE INFORMATION
Received January 19, 2018; accepted August 28, 2018.
Continuing medical education (CME) credit is available for this article. Go 
to http://cme.ahajournals.org to take the quiz. 
The online-only Data Supplement, podcast, and transcript are available 
with this article at https://www.ahajournals.org/doi/suppl/10.1161/circula-
tionaha.118.034516.
Correspondence
Steven P. Marso, MD, Research Medical Center, 2316 E Meyer Blvd, Kansas City, 
MO 64132. Email Steve.Marso@HCAhealthcare.com
Affiliations
Division of Cardiac Surgery (S.V.), St Michael’s Hospital and University of Toron-
to (L.A.L.), Canada. Imperial College London, United Kingdom (N.R.P.). Brigham 
and Women’s Hospital Heart and Vascular Center and Harvard Medical School, 
Boston, MA (D.L.B.). Institute of Life Science, Swansea University, United King-
dom (S.C.B.). University of North Carolina School of Medicine, Chapel Hill 
(J.B.B.). Diabetes Center Bochum-Hattingen, St Josef-Hospital, Ruhr-University 
Bochum, Germany (M.A.N.). Florida Hospital Translational Research Institute for 
Metabolism and Diabetes, Orlando (R.E.P.). Lunenfeld Tanebaum Research Insti-
tute, Mount Sinai Hospital, University of Toronto, Canada (B.Z.). Novo Nordisk 
A/S, Søborg, Denmark (D.D.Ø., T.M.F., S.R.). Hospital Corporation of America 
(HCA) Midwest Health Heart & Vascular Institute, Kansas City, MO (S.P.M.).
Acknowledgments
The authors thank all trial personnel and patients. Editorial and submission sup-
port, limited to formatting and collation of coauthor comments, was provided 
by Watermeadow Medical, an Ashfield Company, part of UDG Healthcare plc, 
funded by Novo Nordisk A/S. We thank Dr Hwee Teoh from St Michael’s Hos-
pital for editorial assistance. Drs Verma, Marso, Ørsted, Fries, and Rasmussen 
had full access to the study data and take responsibility for its integrity and 
data analysis. The authors were fully responsible for all content and editorial 
decisions, involved at all stages of manuscript development, and have approved 
the final version. Drs Verma, Marso, and Bhatt wrote the first draft of the pa-
per. Drs Nauck, Poulter, Bain, Buse, Pratley, Zinman, and Rasmussen were in-
volved in the design, performance, and statistical analysis of the LEADER trial. 
All authors were involved in reviewing and interpreting the data and providing 
further comments and revisions. All authors approved the final version of the 
manuscript.
Sources of Funding
This study was funded by Novo Nordisk A/S.
Disclosures
Dr Verma is President of the Canadian Medical and Surgical Knowledge Transla-
tion Research Group, a federally incorporated not-for-profit physician organization; 
holds a Tier 1 Canada Research Chair in Cardiovascular Surgery; and reports receiv-
ing research grants and/or speaking honoraria from Amgen, AstraZeneca, Bayer 
Healthcare, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, 
Sanofi, Servier, and Valeant. Dr Poulter is president of the International Society of 
Hypertension; has received personal speaker fees from Servier, Takeda, and Novo 
Nordisk A/S; is on advisory boards for AstraZeneca and Novo Nordisk A/S; and 
receives research grants for his research group relating to T2DM from Diabetes UK, 
the National Institute for Health Research Efficacy and Mechanism Evaluation, Julius 
Clinical, and the British Heart Foundation, with a pending grant from Novo Nordisk 
A/S. Dr Bhatt reports the following: advisory board, Cardax, Elsevier Practice Update 
Cardiology, Medscape Cardiology, and Regado Biosciences; board of directors, Bos-
ton Veterans Affairs Research Institute and Society of Cardiovascular Patient Care; 
chair, American Heart Association Quality Oversight Committee; data monitoring 
committee, Baim Institute for Clinical Research (formerly Harvard Clinical Research 
Institute), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Si-
 
nai School of Medicine, and Population Health Research Institute; honoraria, Amer-
ican College of Cardiology (senior associate editor, Clinical Trials and News, ACC.
org; vice-chair, ACC Accreditation Committee), Baim Institute for Clinical Research 
(formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial [Randomized 
Evaluation of Dual Antithrombotic Therapy with Dabigatran Versus Triple Therapy 
With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percu-
taneous Coronary Intervention] steering committee funded by Boehringer Ingel-
heim); editor in chief, Harvard Heart Letter, Belvoir Publications; clinical trial steering 
committees, Duke Clinical Research Institute; editor in chief, Journal of Invasive 
Cardiology, HMP Global; guest editor and associate editor, Journal of the American 
College of Cardiology; clinical trial steering committee, Population Health Research 
Institute; chief medical editor, Cardiology Today’s Intervention, Slack Publications; 
secretary/treasurer, Society of Cardiovascular Patient Care; Continuing Medical 
Education steering committees, WebMD; deputy editor, Clinical Cardiology; chair, 
National Cardiovascular Data Registry–Acute Coronary Treatment and Interventions 
Outcomes Network Registry Steering Committee; chair, Veterans Affairs Clinical As-
sessment Reporting and Tracking Research and Publications Committee; research 
funding, Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, 
Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, 
Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company; 
royalties, Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s 
Heart Disease); site coinvestigator, Biotronik, Boston Scientific, St Jude Medical 
(now Abbott), and Svelte; trustee, American College of Cardiology; and unfunded 
research, FlowCo, Merck, Novo Nordisk, PLx Pharma, and Takeda. Dr Bain reports 
research grants (includes principal investigator, collaborator, or consultant and 
pending grants, as well as grants already received) from Healthcare and Research 
Wales (Welsh Government) and Novo Nordisk A/S; other research support from 
Healthcare and Research Wales (Welsh Government) and  infrastructure support; 
honoraria from Novo Nordisk A/S, Sanofi, Lilly, Boehringer Ingelheim, and Merck; 
and ownership interest in Glycosmedia (diabetes online news service). Dr Buse re-
ports consulting fees paid to his institution and travel support from Novo Nordisk 
A/S, Eli Lilly, Bristol-Myers Squibb, GI Dynamics, Elcelyx, Merck, Metavention, vTv 
Therapeutics, PhaseBio, AstraZeneca, Dance Biopharm, Quest Diagnostics, Sanofi-
Aventis, Lexicon Pharmaceuticals, Orexigen Therapeutics, Takeda Pharmaceuticals, 
Adocia, and Roche; grant support from Eli Lilly, Bristol-Myers Squibb, GI Dynam-
ics, Merck, PhaseBio, AstraZeneca, Medtronic, Sanofi, Tolerex, Osiris Therapeutics, 
Halozyme Therapeutics, Johnson & Johnson, Andromeda, Boehringer Ingelheim, 
GlaxoSmithKline, Astellas Pharma, MacroGenics, Intarcia Therapeutics, Lexicon, 
Senseonics, Scion NeuroStim, Orexigen Therapeutics, Takeda Pharmaceuticals, 
Theracos, Roche, and the National Institutes of Health (UL1TR002489); fees and 
stock options from PhaseBio and Mellitus Health; and boards of the AstraZeneca 
Healthcare Foundation and Bristol-Myers Squibb Together on Diabetes Founda-
tion. Dr Leiter reports consultant and speaker fees from AstraZeneca, Boehringer 
Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk A/S, Sanofi, and Servier, as well 
as research grants or support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, 
GlaxoSmithKline, Janssen, Merck, Novo Nordisk A/S, and Sanofi. Dr Nauck reports 
advisory boards or consultancy for AstraZeneca, Boehringer Ingelheim, Eli Lilly & 
Co, Fractyl, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and 
Novo Nordisk A/S, as well as speakers’ bureaus for AstraZeneca, Boehringer Ingel-
heim, Eli Lilly & Co, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and Novo 
Nordisk A/S. His institution has received grant support from AstraZeneca, Eli Lilly & 
Co, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and Novo 
Nordisk A/S. Dr Pratley reports research grants from Gilead Sciences, Lexicon Phar-
maceuticals, Ligand Pharmaceuticals Inc, Lilly, Merck, Novo Nordisk A/S, Sanofi-
Aventis US LLC, and Takeda; speaker fees from AstraZeneca, Novo Nordisk A/S, and 
Takeda; and consultant fees from AstraZeneca, Boehringer Ingelheim, Eisai, Inc, 
GlaxoSmithKline, Janssen Scientific Affairs LLC, Ligand Pharmaceuticals Inc, Lilly, 
Merck, Novo Nordisk A/S, Pfizer, and Takeda. All payments are made directly to his 
employer (Florida Hospital). Dr Zinman reports consulting fees from Merck, Novo 
Nordisk A/S, Sanofi-Aventis, Eli Lilly, AstraZeneca, Janssen, and Boehringer Ingel-
heim. Drs Ørsted, Rasmussen, and Monk Fries are Novo Nordisk A/S employees 
and shareholders. Dr Marso reports consulting fees from Novo Nordisk A/S and St 
Jude Medical and research support from Novo Nordisk A/S, Terumo, The Medicines 
Company, AstraZeneca, and Bristol-Myers Squibb.
REFERENCES
1. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, 
Im K, Wilson PW, Bhatt DL; REACH Registry Investigators. Impact of diabe-
tes mellitus on hospitalization for heart failure, cardiovascular events, and 
death: outcomes at 4 years from the Reduction of Atherothrombosis for
Continued Health (REACH) registry. Circulation. 2015;132:923–931. doi:
10.1161/CIRCULATIONAHA.114.014796
2. Centers for Disease Control and Prevention. National diabetes statis-
tics report. 2014. https://www.cdc.gov/diabetes/pdfs/data/2014-report-
estimates-of-diabetes-and-its-burden-in-the-united-states.pdf. Accessed
January 18, 2017.
3. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin 
R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stamp-
fer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N,
White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose con-
centration, and risk of vascular disease: a collaborative meta-analysis of
102 prospective studies. Lancet. 2010;375:2215–2222. doi: 10.1016/
S0140-6736(10)60484–9
4. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im
K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. Reduction in
ischemic events with ticagrelor in diabetic patients with prior myocardial
infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732–2740.
doi: 10.1016/j.jacc.2016.03.529
5. Bhatt DL. Antiplatelet therapy following myocardial infarction in patients
with diabetes. JAMA. 2012;308:921–922. doi: 10.1001/2012.jama.11467
6. Hussain MA, Al-Omran M, Mamdani M. Efficacy of a guideline-rec-
ommended risk-reduction program to improve cardiovascular and
limb outcomes in patients with peripheral arterial disease. J Vasc Surg. 
2016;64:535. doi: 10.1016/j.jvs.2016.06.055
7. Burrows NR, Li Y, Gregg EW, Geiss LS. Declining rates of hospitalization for 
selected cardiovascular disease conditions among adults aged ≥35 years
with diagnosed diabetes, U.S., 1998–2014. Diabetes Care. 2018;41:293–
302. doi: 10.2337/dc17-1259
8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck
MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, 
Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER
Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 dia-
betes. N Engl J Med. 2016a;375:311–322. doi: 10.1056/NEJMoa1603827
9. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wil-
son PW, Alberts MJ, D’Agostino R, Liau CS, Mas JL, Röther J, Smith SC
Jr, Salette G, Contant CF, Massaro JM, Steg PG; REACH Registry In-
vestigators. Comparative determinants of 4-year cardiovascular event
rates in stable outpatients at risk of or with atherothrombosis. JAMA. 
2010;304:1350–1357. doi: 10.1001/jama.2010.1322
10. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Po-
cock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB,
Moses AC, Buse JB. Design of the Liraglutide Effect and Action in Dia-
betes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Am 
Heart J. 2013;166:823–830.e5. doi: 10.1016/j.ahj.2013.07.012
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribu-
tion of a competing risk. J Am Stat Assoc. 1999;94:496–509. doi:
10.2307/2670170.
12. Altman DG, Andersen PK. Calculating the number needed to treat for
trials where the outcome is time to an event. BMJ. 1999;319:1492–1495.
13. Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA,
Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Ras-
mussen S, Leiter LA; LEADER Publication Committee on behalf of the 
LEADER Trial Investigators. Effect of liraglutide on cardiovascular events 
in patients with type 2 diabetes mellitus and polyvascular disease: re-
sults of the LEADER Trial. Circulation. 2018;137:2179–2183. doi: 
10.1161/CIRCULATIONAHA.118.033898
14. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, 
Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald
E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention 
of cardiovascular events in the subgroup of patients with previous myo-
cardial infarction: a collaborative meta-analysis of randomized trials. Eur 
Heart J. 2016;37:390–399. doi: 10.1093/eurheartj/ehv443
15. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, 
Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux 
P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mor-
tality in patients treated with extended duration dual antiplatelet therapy
after drug-eluting stent implantation: a pairwise and bayesian network
meta-analysis of randomised trials. Lancet. 2015;385:2371–2382. doi:
10.1016/S0140-6736(15)60263-X
16. Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, Yanaga-
wa B, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Should dual antiplate-
let therapy be used in patients following coronary artery bypass surgery?
A meta-analysis of randomized controlled trials. BMC Surg. 2015;15:112. 
doi: 10.1186/s12893-015-0096-z
17. Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira
J, Kuder JF, Murphy SA, Wiviott SD, Kurtz C, Honarpour N, Keech AC,
Sever PS, Pedersen TR. Clinical benefit of evolocumab by severity and ex-
tent of coronary artery disease: an analysis from FOURIER. Circulation. 
2018;138:756–766. doi: 10.1161/CIRCULATIONAH.
18. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB,
Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman
P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF;
EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular
outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239. doi:
10.1056/NEJMoa1612917.
19. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw 
W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Col-
laborative Group. Canagliflozin for primary and secondary prevention of
cardiovascular events: results from the CANVAS program (Canagliflozin
Cardiovascular Assessment Study). Circulation. 2018;137:323–334. doi:
10.1161/CIRCULATIONAHA.117.032038
20. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, 
Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Petters-
son J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular
outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–
1844. doi: 10.1056/NEJMoa1607141
21. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Car-
diovascular actions and clinical outcomes with glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 
2017;136:849–870. doi: 10.1161/CIRCULATIONAHA.117.028136
